Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:NRIX NYSE:PLX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.20-3.6%$7.12$5.64▼$16.76$737.51M-1.261.50 million shs783,651 shsNRIXNurix Therapeutics$9.84-1.9%$9.46$8.18▼$29.56$756.53M2.331.31 million shs602,735 shsPLXProtalix BioTherapeutics$1.86-22.5%$1.91$1.01▼$3.10$148.30M-0.13855,025 shs5.50 million shsRZLTRezolute$8.69-2.0%$7.86$2.21▼$9.72$789.30M0.041.63 million shs728,018 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%-0.48%-0.14%+12.50%-52.03%NRIXNurix Therapeutics0.00%+0.82%+9.70%-12.22%-61.88%PLXProtalix BioTherapeutics0.00%-21.19%0.00%+28.28%+70.64%RZLTRezolute0.00%+5.08%+5.98%+61.22%+75.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.20-3.6%$7.12$5.64▼$16.76$737.51M-1.261.50 million shs783,651 shsNRIXNurix Therapeutics$9.84-1.9%$9.46$8.18▼$29.56$756.53M2.331.31 million shs602,735 shsPLXProtalix BioTherapeutics$1.86-22.5%$1.91$1.01▼$3.10$148.30M-0.13855,025 shs5.50 million shsRZLTRezolute$8.69-2.0%$7.86$2.21▼$9.72$789.30M0.041.63 million shs728,018 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%-0.48%-0.14%+12.50%-52.03%NRIXNurix Therapeutics0.00%+0.82%+9.70%-12.22%-61.88%PLXProtalix BioTherapeutics0.00%-21.19%0.00%+28.28%+70.64%RZLTRezolute0.00%+5.08%+5.98%+61.22%+75.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.00Buy$25.29251.19% UpsideNRIXNurix Therapeutics 2.76Moderate Buy$27.79182.38% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00706.45% UpsideRZLTRezolute 2.88Moderate Buy$14.5066.86% UpsideCurrent Analyst Ratings BreakdownLatest PLX, RZLT, NRIX, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $33.0010/14/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$16.00 ➝ $15.0010/13/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.0010/13/2025DAWNDay One BiopharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/10/2025NRIXNurix TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.0010/10/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $28.0010/10/2025NRIXNurix TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $32.0010/8/2025DAWNDay One BiopharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NRIXNurix TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RZLTRezoluteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DAWNDay One BiopharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M5.62N/AN/A$4.99 per share1.44NRIXNurix Therapeutics$83.69M9.04N/AN/A$4.84 per share2.03PLXProtalix BioTherapeutics$61.95M2.39$0.10 per share17.80$0.47 per share3.96RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.97N/AN/AN/A-292.50%-53.57%-40.82%N/APLXProtalix BioTherapeutics$8.31M$0.07N/A6.00N/A-21.03%-30.89%-11.74%N/ARZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)Latest PLX, RZLT, NRIX, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q1 2026RZLTRezolute-$0.27N/AN/AN/AN/AN/A10/29/2025Q3 2025DAWNDay One Biopharmaceuticals-$0.28N/AN/AN/A$38.20 millionN/A10/9/2025Q3 2025NRIXNurix Therapeutics-$0.84-$1.03-$0.19-$1.03$16.06 million$7.89 million9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53NRIXNurix TherapeuticsN/A5.355.35PLXProtalix BioTherapeuticsN/A1.981.27RZLTRezoluteN/A14.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%NRIXNurix TherapeuticsN/APLXProtalix BioTherapeutics16.53%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%NRIXNurix Therapeutics7.40%PLXProtalix BioTherapeutics6.50%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableNRIXNurix Therapeutics30076.88 million71.19 millionOptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionableRZLTRezolute4090.83 million77.40 millionOptionablePLX, RZLT, NRIX, and DAWN HeadlinesRecent News About These CompaniesRezolute to Participate in Upcoming Investor ConferencesOctober 15, 2025 | globenewswire.comRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 9, 2025 | globenewswire.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Rezolute (NASDAQ:RZLT)October 9, 2025 | marketbeat.comRezolute, Inc. ($RZLT) CEO 2025 Pay RevealedOctober 7, 2025 | quiverquant.comQRezolute (NASDAQ:RZLT) Sets New 1-Year High - Still a Buy?October 2, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Rezolute FY2026 EarningsOctober 1, 2025 | marketbeat.comWe're Not Very Worried About Rezolute's (NASDAQ:RZLT) Cash Burn RateSeptember 29, 2025 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from AnalystsSeptember 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Stock Price Up 7.6% - Still a Buy?September 26, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Still a Buy?September 25, 2025 | marketbeat.comGoldman Sachs Group Inc. Invests $685,000 in Rezolute, Inc. $RZLTSeptember 25, 2025 | marketbeat.comRezolute's (RZLT) "Buy" Rating Reiterated at GuggenheimSeptember 22, 2025 | marketbeat.comWhat is Wedbush's Forecast for Rezolute Q3 Earnings?September 22, 2025 | marketbeat.comHC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)September 22, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Time to Buy?September 20, 2025 | marketbeat.comHC Wainwright Weighs in on Rezolute FY2030 EarningsSeptember 20, 2025 | marketbeat.comRezolute's (RZLT) Outperform Rating Reaffirmed at WedbushSeptember 19, 2025 | marketbeat.comRezolute price target raised to $20 from $15 at MaximSeptember 19, 2025 | msn.comBTIG Research Reiterates "Buy" Rating for Rezolute (NASDAQ:RZLT)September 19, 2025 | marketbeat.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18, 2025 | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLX, RZLT, NRIX, and DAWN Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.20 -0.27 (-3.61%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$7.20 0.00 (-0.07%) As of 10/17/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Nurix Therapeutics NASDAQ:NRIX$9.84 -0.19 (-1.89%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.72 -0.12 (-1.18%) As of 10/17/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Protalix BioTherapeutics NYSE:PLX$1.86 -0.54 (-22.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.81%) As of 10/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Rezolute NASDAQ:RZLT$8.69 -0.18 (-2.03%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.01 +0.32 (+3.68%) As of 10/17/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
